Gabor T Marth
Overview
Explore the profile of Gabor T Marth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
16332
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Black G, Huang X, Qiao Y, Moos P, Sampath D, Stephens D, et al.
Genome Res
. 2025 Feb;
PMID: 39965935
Bruton's tyrosine kinase (BTK) inhibitors are effective for the treatment of chronic lymphocytic leukemia (CLL) due to BTK's role in B cell survival and proliferation. Treatment resistance is most commonly...
2.
Sederman C, Yang C, Cortes-Sanchez E, Di Sera T, Huang X, Scherer S, et al.
bioRxiv
. 2025 Jan;
PMID: 39763776
Precision oncology matches tumors to targeted therapies based on the presence of actionable molecular alterations. However, most tumors lack actionable alterations, restricting treatment options to cytotoxic chemotherapies for which few...
3.
Huang X, Pomicter A, Ahmann J, Qiao Y, Chen O, George T, et al.
Blood Cancer J
. 2024 Oct;
14(1):179.
PMID: 39402020
No abstract available.
4.
Black G, Huang X, Qiao Y, Moos P, Sampath D, Stephens D, et al.
bioRxiv
. 2024 Apr;
PMID: 38559060
Bruton's tyrosine kinase (BTK) inhibitors are effective for the treatment of chronic lymphocytic leukemia (CLL) due to BTK's role in B cell survival and proliferation. Treatment resistance is most commonly...
5.
Chamberlin J, Lee Y, Marth G, Quinlan A
Genome Res
. 2024 Feb;
34(2):179-188.
PMID: 38355308
A mechanistic understanding of the biological and technical factors that impact transcript measurements is essential to designing and analyzing single-cell and single-nucleus RNA sequencing experiments. Nuclei contain the same pre-mRNA...
6.
Qiao Y, Huang X, Moos P, Ahmann J, Pomicter A, Deininger M, et al.
Genome Res
. 2024 Jan;
34(1):94-105.
PMID: 38195207
Genetic and gene expression heterogeneity is an essential hallmark of many tumors, allowing the cancer to evolve and to develop resistance to treatment. Currently, the most commonly used data types...
7.
Pitman A, Huang X, Marth G, Qiao Y
Bioinformatics
. 2023 Jul;
39(8).
PMID: 37498562
Motivation: In time-critical clinical settings, such as precision medicine, genomic data needs to be processed as fast as possible to arrive at data-informed treatment decisions in a timely fashion. While...
8.
Black G, Huang X, Qiao Y, Tarapcsak S, Rogers K, Misra S, et al.
Blood
. 2022 Apr;
140(4):401-405.
PMID: 35476648
No abstract available.
9.
Guillen K, Fujita M, Butterfield A, Scherer S, Bailey M, Chu Z, et al.
Nat Cancer
. 2022 Feb;
3(2):232-250.
PMID: 35221336
Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures...
10.
Primo Jr V, Rezvani Y, Farrell A, Murphy C, Lou J, Vajdi A, et al.
mSystems
. 2021 Dec;
6(6):e0119621.
PMID: 34874774
Evolve and resequencing (E&R) was applied to lab adaptation of Toxoplasma gondii for over 1,500 generations with the goal of mapping host-independent virulence traits. Phenotypic assessments of steps across the...